MAKING GREAT DRUGS BETTER

News

Re-Vana Therapeutics Strengthens Executive Team with the Appointments of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of R&D

by | Feb 23, 2021 | News | 0 comments

New Appointments Bring Extensive Ocular Drug Delivery, Strategy and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into the Eye to Treat Sight-Threatening Eye Diseases

Belfast, Northern Ireland – 23 February 2021 – Re-Vana Therapeutics, a specialty ocular therapeutic and drug delivery company that specializes in the development of photo-crosslinked drug delivery technologies for both biologic and small molecules, today announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a broad range of ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma. …

Read the entire press release >>

Re-Vana: Vision In The Future